Skip to content

Study · Non-randomized trial · 2020

8 results

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.

Meier JJ, Menge BA, Schenker N, Erdmann S, Kahle-Stephan M, Schliess F, Kapitza C, Nauck MA

Diabetes, obesity & metabolism26 Dec 2019Cited by 24 (Europe PMC)

PMID31793165 (opens in a new tab)DOI10.1111/dom.13935 (opens in a new tab)PepBankPUB-31793165
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, lixisenatide mainly reduced postprandial glycaemia after breakfast (P < 0.05).

    In plain wordsIn patients with diabetes taking metformin, lixisenatide reduced glucose after breakfast relative to pretreatment.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glycaemia after breakfast
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.05
    after breakfast

    Source sentences

    Summary
    Lixisenatide mainly reduced postprandial glycaemia, while insulin glargine mainly reduced fasting glucose after breakfast (P < 0.05).
    2 context sentences
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  2. 02HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, the postprandial glucose reduction with lixisenatide was partially preserved after a late lunch (P < 0.05).

    In plain wordsIn patients with diabetes taking metformin, glucose reduction from pretreatment with lixisenatide persisted partly after a late lunch.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glycaemia after late lunch
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Measurements

    P value
    < 0.05
    after late lunch

    Source sentences

    Summary
    This was partially preserved after a late lunch (P < 0.05).
    3 context sentences
    Summary · context
    Lixisenatide mainly reduced postprandial glycaemia, while insulin glargine mainly reduced fasting glucose after breakfast (P < 0.05).
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  3. 03HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, lixisenatide significantly reduced insulin secretion after breakfast.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide reduced insulin release after breakfast relative to pretreatment.

    Peptide
    Lixisenatide
    Outcome
    DecreaseInsulin secretion after breakfast
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    After breakfast, lixisenatide reduced insulin secretion and glucagon levels significantly.
    2 context sentences
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  4. 04HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, lixisenatide significantly reduced glucagon levels after breakfast.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide reduced glucagon after breakfast relative to pretreatment.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucagon levels after breakfast
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    After breakfast, lixisenatide reduced insulin secretion and glucagon levels significantly.
    2 context sentences
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  5. 05HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, the insulin secretion reduction with lixisenatide was lost after a late lunch.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide's reduction in insulin release from pretreatment was absent after a late lunch.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedInsulin secretion after late lunch
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    These effects were lost after a late lunch.
    3 context sentences
    Summary · context
    After breakfast, lixisenatide reduced insulin secretion and glucagon levels significantly.
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  6. 06HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, the glucagon reduction with lixisenatide was lost after a late lunch.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide's reduction in glucagon from pretreatment was absent after a late lunch.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedGlucagon levels after late lunch
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    These effects were lost after a late lunch.
    3 context sentences
    Summary · context
    After breakfast, lixisenatide reduced insulin secretion and glucagon levels significantly.
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  7. 07HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, lixisenatide slowed gastric emptying after breakfast.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide slowed stomach emptying after breakfast relative to pretreatment.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying after breakfast
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastric emptying was slowed by lixisenatide, but not by insulin glargine after breakfast.
    2 context sentences
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.
  8. 08HumanNon-randomized trialMechanism

    In metformin-treated patients with diabetes, lixisenatide slightly accelerated gastric emptying after a late lunch.

    In plain wordsIn patients with diabetes taking metformin, lixisenatide slightly accelerated stomach emptying after a late lunch relative to pretreatment.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGastric emptying after late lunch
    Study

    n: not reported in source

    Comparator
    Before treatment
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    After the late lunch, lixisenatide slightly accelerated gastric emptying.
    2 context sentences
    Summary · context
    Twenty-eight metformin-treated patients with type 2 diabetes were randomly assigned to treatment sequences with either lixisenatide or insulin glargine alone for 4 weeks, and a combination of both treatments for 4 weeks.
    Summary · context
    Metabolic examinations were performed before and after each treatment period following breakfast and a late lunch 8 hours later.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.